Cyclacel Pharmaceuticals Inc: Wellness Industry Loser

New York, NY -- (SBWIRE) -- 12/06/2012 -- Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) produces treatments that utilize the power of the defense mechanisms to treat melanoma and other serious illnesses. The Company produces exclusive techniques of antibody technological innovation to develop antibody-based products for the applications in immunology, oncology, and contagious illnesses. Xcyte Therapies is currently conducting Phase I/II clinical studies in hormone-refractory prostate melanoma, multiple myeloma and serious lymphocytic the leukemia disease.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) made a new 52-week high of $8.18 and shut at $7.59, up 19.15 on information of demonstration of Stage 3 medical test outcomes for the therapy of seniors sufferers with recently clinically diagnosed serious myeloid the leukemia disease (AML) handled with sapacitabine and decitabine applied in changing periods will be provided at a poster demonstration during the 54th Yearly Conference of the United states Community of Hematology (ASH) in The atlanta area, on Weekend, Dec 9, 2012.

Cyclacel Pharmaceuticals Inc (NGM:CYCC) is very effective these days and exchanged between $6.86 - 8.10 with complete exchanged number of 1029368 stocks. At a present cost of 7.25, CYCC is -0.34 - -4.48% from the past near of $7.59. Moreover, At Current Industry Price, CYCC is in range of +24.50% from its 50-day Going Regular cost of $5.8233 and +66.48% from its 200-day Going Regular cost of $4.3548.

For a FREE CYCC Specialized Research, please check out

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz